<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193933</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-2009</org_study_id>
    <nct_id>NCT01193933</nct_id>
  </id_info>
  <brief_title>Multicenter Clinical Trial for Adult Ph-negative ALL. Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity</brief_title>
  <official_title>Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. evaluation of blast clearance in b/m after 7 days of prednisolone prephase and the
           efficacy of its substitution by dexamethasone if blast count is 25% and more

        2. feasibility for adults of &quot;no interruptions&quot; protocol with 8 weeks induction and 14
           weeks consolidation followed by 2-years maintenance.

        3. tolerability and efficacy in adults of the prolonged L-asparaginase application (total
           proposed dose 560.000 IU)

        4. feasibility and efficacy of autologous stem cell transplantation for T-cell ALL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The blast count in b/m after 7 days of prednisolone &gt;25% was shown in 64% of patients.
           The substitution of prednisolone by dexamethasone did not influence survival.

        2. &quot;no interruptions&quot; induction was performed in 48% of patients.

        3. In 19% of patients the L-asparaginase therapy was stopped due to toxicity.

        4. Autologous stem cell transplantation was done in 20% of T-cell ALL patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of adult ALL patients who tolerated the non-interrupted treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients who finished the protocol without any deviation, who were off the protocol due to toxicity, in whom the treatment schedule was modified and respectively the antileukemia efficacy in those subgroups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of prolonged L-asparaginase in adult patients</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients who tolerated the scheduled L-asparaginase by dose and time sequence, proportion of patients shifted to PEG-asparaginase, in whom L-asparaginase was stopped and, respectively, the survival without leukemia of those patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Ph-negative Adult Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <description>prolonged L-asparaginase application at 10.000 IU weekly in induction, once in two weeks in 14 weeks consolidation, twice a month in maintenance (total proposed dose 560.000 IU)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ph-negative precursors ALL

          -  age 15-55 years

          -  nontreated

          -  Eastern Cooperative Oncology Group criterion status 0-3

        Exclusion Criteria:

          -  B-mature ALL

          -  Ph-positivity

          -  pretreatment

          -  Eastern Cooperative Oncology Group criterion status 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeri G Savchenko, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena N Parovichnikova, Ass Prof</last_name>
    <phone>+7-495-612-43-13</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Russian Acute Lymphoblastic Leukemia Study group</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena N Parovichnikova, Ass Prof</last_name>
      <phone>+7-495-612-43-13</phone>
      <email>elenap@blood.ru</email>
    </contact>
    <investigator>
      <last_name>Julia R Davidyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Yu Baranova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatyana I Kaporskaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena V Kondakova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatyana V Ryltzova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey N Bondarenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrey N Sokolov, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>August 31, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>adult ALL</keyword>
  <keyword>Ph-negative</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>L-asparaginase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
